793695-85-9

Basic information

• Product Name: 2-(BROMOMETHYL)-1-CHLORO-4-IODOBENZENE
• Synonyms: 2-(BROMOMETHYL)-1-CHLORO-4-IODOBENZENE;Benzene,2-(broMoMethyl)-1-chloro-4-iodo-;2-Chloro-5-iodobenzyl broMide;2-(Bromomethyl)-4-iodochlorobenzene;DFDCZEQSQMAKJJ-UHFFFAOYSA-N
• CAS NO: 793695-85-9
• Molecular Formula: C₇H₅BrClI
• Molecular Weight: 331.38
• Mol File: 793695-85-9.mol
• Article Data: 6

Chemical Properties

• Melting Point: 94-95 °C
• Boiling Point: 309.1±32.0 °C(Predicted)
• Appearance: /
• Density: 2.166±0.06 g/cm3(Predicted)
• CAS DataBase Reference: 2-(BROMOMETHYL)-1-CHLORO-4-IODOBENZENE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(BROMOMETHYL)-1-CHLORO-4-IODOBENZENE(793695-85-9)
• EPA Substance Registry System: 2-(BROMOMETHYL)-1-CHLORO-4-IODOBENZENE(793695-85-9)

Safety Data

• Hazardous Substances Data: 793695-85-9(Hazardous Substances Data)

Usage

General Description

2-(Bromomethyl)-1-chloro-4-iodobenzene, also known as 2-bromo-1-chloro-4-iodotoluene, is an organic compound with the chemical formula C7H6BrClI. It is a benzene derivative that contains bromine, chlorine, and iodine atoms attached to the benzene ring. This chemical is commonly used as an intermediate in the synthesis of pharmaceuticals, agrochemicals, and other organic compounds. It is also used in the production of dyes and other industrial chemicals. 2-(Bromomethyl)-1-chloro-4-iodobenzene is a colorless to pale yellow liquid with a distinct odor and is classified as a hazardous chemical, requiring proper handling and storage.

Upstream product

• 116632-41-8 1-chloro-4-iodo-2-methylbenzene 

Downstream Products

• 1103738-29-9 1-chloro-2-(4-ethoxybenzyl)-4-iodobenzene 
• 1067197-12-9 methyl N-[[2-chloro-5-[1-(4-methylphenyl)methyl-1H-1,2,3-triazol-4-yl]phenyl]methyl]carbamate 
• 1067197-09-4 methyl N-[[2-chloro-5-[2-(4-methylphenyl)methyl-2H-1,2,3-triazol-4-yl]phenyl]methyl]carbamate 
• 1067197-10-7 methyl N-[[2-chloro-5-[2-(4-chlorophenyl)-2H-1,2,3-triazol-4-yl]phenyl]methyl]carbamate 
• 1067197-11-8 methyl N-[[2-chloro-5-[1-(4-chlorophenyl)-1H-1,2,3-triazol-4-yl]phenyl]methyl]carbamate 
• 1067197-08-3 methyl N-[[2-chloro-5-(1H-1,2,3-triazol-5-yl)phenyl]methyl]carbamate 
• 251084-97-6 methyl N-[[2-chloro-5-ethynylphenyl]methyl]carbamate 
• 251085-25-3 methyl N-[[2-chloro-5-[2-(trimethylsilyl)ethynyl]phenyl]methyl]carbamate 
• 1067197-20-9 methyl [(2-chloro-5-iodophenyl)methyl]carbamate 
• 1049811-45-1 3-(2-Chloro-5-iodo-benzyloxy)-propan-1-ol 
• 793695-74-6 (1'S,2'R,3'S,4'R,5'S)-4'-[6-(2-chloro-5-(3-hydroxypropynyl)benzylamino)-2-chloropurin-9-yl]-2',3'-O-isopropylidenebicyclo[3.1.0]haxane-1'-carboxylic acid ethyl ester 
• 793695-65-5 (1'S,2'R,3'S,4'R,5'S)-4'-[6-(2-chloro-5-iodobenzylamino)-2-chloropurin-9-yl]-2',3'-O-isopropylidenebicyclo[3.1.0]haxane-1'-carboxylic acid ethyl ester 
• 793695-92-8 2-chloro-5-(3-hydroxypropynyl)benzylamine 
• 793695-90-6 2-chloro-5-iodobenzylamine 

Relevant articles and documents

First Contact: 7-Phenyl-2-Aminoquinolines, Potent and Selective Neuronal Nitric Oxide Synthase Inhibitors That Target an Isoform-Specific Aspartate

Inhibition of neuronal nitric oxide synthase (nNOS), an enzyme implicated in neurodegenerative disorders, is an attractive strategy for treating or preventing these diseases. We previously developed several classes of 2-aminoquinoline-based nNOS inhibitor

2-(1,2,3-TRIAZOL-2-YL)BENZAMIDE AND 3-(1,2,3-TRIAZOL-2-YL)PICOLINAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS

The present invention relates to 2-(1,2,3-triazol-2-yl)benzamide and 3-(1,2,3-triazol-2- yl)picolinamide derivatives of formula (I) Formula (I) wherein Ar1, Q, and R1 to R5 are as described in the description, to their pre

PURINE DERIVATIVES AS A3 AND A1 ADENOSINE RECEPTOR AGONISTS

Disclosed are (N)-methanocarba adenine nucleosides of the formula: [Formula] as highly potent A3 adenosine receptor agonists, pharmaceutical compositions comprising such nucleosides, and a method of use of these nucleosides, wherein R1-R6 are as defined in the specification. These nucleosides are contemplated for use in the treatment a number of diseases, for example, inflammation, cardiac ischemia, stroke, asthma, diabetes, and cardiac arrhythmias. The invention also provides compounds that are agonists of both A1 and A3 adenosine receptors for use in cardioprotection.